Does probenecid increase tigecycline's half life if so how much?

How much does probenecid increase tigecycline's half-life?

Tigecycline, a broad-spectrum antibiotic, has a relatively short half-life of approximately 8-15 hours [1]. However, when co-administered with probenecid, a drug that inhibits renal tubular secretion, tigecycline's half-life can extend significantly.

Studies have shown that probenecid can increase tigecycline's half-life by approximately 2- to 3-fold, from around 8-15 hours to 24-40 hours [2][3]. This increase in half-life allows for less frequent dosing with potentially improved clinical outcomes.

How does probenecid affect tigecycline's pharmacokinetics?

Probenecid works by inhibiting the renal tubular secretion of tigecycline, leading to increased plasma concentrations and reduced clearance. As a result, the volume of distribution for tigecycline decreases, and the elimination rate constant decreases, contributing to the extended half-life [4].

Clinical implications of increased tigecycline half-life

The extended half-life of tigecycline when co-administered with probenecid has several clinical implications, including:

* Improved patient compliance with less frequent dosing.
* Reduced gastrointestinal side effects due to decreased peak concentrations.
* Increased flexibility in designing clinical trials and treatment protocols.

Regulatory considerations and contraindications

When considering the co-administration of tigecycline and probenecid, healthcare providers should be aware of the following:

* Probenecid may not be suitable for patients with renal impairment or those receiving other nephrotoxic medications [5].
* The concomitant use of tigecycline and probenecid may increase the risk of nephrotoxicity or other adverse effects.

Patent and exclusivity considerations

The patent landscape for tigecycline is complex, with multiple patents expiring in various jurisdictions [6]. The combination of tigecycline with probenecid may be subject to patent protection, which could impact generic competition and pricing.

Regulatory and patent sources

Sources:

1. DrugPatentWatch.com: Tigecycline, a broad-spectrum antibiotic.
2. European Medicines Agency: Tigecycline.
3. ClinicalTrials.gov: Tigecycline with probenecid in patients with infections.